DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

Dyne Therapeutics, Inc. (($DYN)) announced an update on their ongoing clinical study. Dyne Therapeutics, Inc. is conducting a study titled A ...

Hatteras was founded in 2000 with the closing of Hatteras Venture Partners I, a seed-stage venture fund with $2.93 million in capital. Today, the firm is focused on seed- and early stage companies in ...

Satellos Bioscience ( ($TSE:MSCL) ) has provided an announcement. Satellos Bioscience reported positive results from its Phase 1b study of ...

Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive ...